Skip to main content
Neuland Laboratories Limited. logo

Neuland Laboratories Limited. — Investor Relations & Filings

Ticker · NEULANDLAB ISIN · INE794A01010 LEI · 335800AVHZURTYQ17N08 BSE.NS Manufacturing
Open in API
Filings indexed 943 across all filing types
Latest filing 2026-05-31 Regulatory Filings
Country IN India
Listing BSE.NS NEULANDLAB

About Neuland Laboratories Limited.

https://www.neulandlabs.com

Neuland Laboratories Limited specializes in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and provides comprehensive Custom Manufacturing Solutions (CMS). The company focuses on complex chemistry and high-quality standards, operating state-of-the-art manufacturing facilities that comply with international regulatory requirements, including those of the USFDA and EDQM. Its product portfolio spans diverse therapeutic areas such as cardiovascular, central nervous system, anti-infectives, and antiasthmatics. Neuland supports pharmaceutical companies globally through the entire lifecycle of a drug, from early-stage clinical development to commercial-scale production. By leveraging advanced technical expertise and a robust quality management system, the organization delivers reliable chemical synthesis and process optimization services to both innovator and generic drug manufacturers.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 82% confidence The document is an intimation under Regulation 30 of the SEBI Listing Obligations to stock exchanges, notifying a schedule of analyst/institutional investor meetings. It does not contain financial results, presentations, or voting outcomes, nor is it a report or proxy solicitation. It is a general regulatory disclosure under listing rules, fitting the fallback category for miscellaneous compliance announcements. Therefore, it should be classified as a Regulatory Filing (RNS).
2026-05-31 English
Intimation about Schedule of Analyst / Institutional Investor Meeting on June 5, 2026
Regulatory Filings Classification · 90% confidence The document is a notification under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements, providing the schedule of analyst/institutional investor meetings. It does not contain financial results, presentations, or substantive report content; it is a regulatory disclosure of an upcoming event. It best fits the fallback category for miscellaneous regulatory announcements.
2026-05-31 English
Intimation about Schedule of Analyst / Institutional Investor Meeting on May 28, 2026
Regulatory Filings Classification · 78% confidence The document is an intimation under Regulation 30 of SEBI LODR to stock exchanges disclosing the schedule of analyst/institutional investor meetings. It does not contain financial statements, earnings details, or presentation slides; instead it is a regulatory announcement of an upcoming investor engagement. This falls under general regulatory filings (disclosures under listing regulations) rather than a specific financial report or investor presentation itself. Hence it is classified as Regulatory Filings (RNS).
2026-05-22 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 85% confidence The document is an intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, informing stock exchanges about upcoming analyst/institutional investor meetings. It does not contain financial statements, results, or detailed presentations—it is a general regulatory announcement to the exchanges. This fits the ‘Regulatory Filings (RNS)’ category as a material event disclosure under listing rules.
2026-05-22 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 95% confidence The document is a notice to the stock exchange enclosing the full transcript of the Q4 & FY26 earnings conference call held on May 12, 2026, followed by the verbatim call transcript (moderator, management remarks, Q&A preparation). This clearly matches the definition of a Call Transcript (CT).
2026-05-16 English
Transcript of the Earnings Call conducted on May 12, 2026
Call Transcript Classification · 93% confidence The document consists of a letter to the stock exchange enclosing the full text of the Q4 & FY26 earnings conference call held on May 12, 2026, followed by the complete transcript including management remarks and Q&A. This exactly matches the definition of a Call Transcript (CT).
2026-05-16 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.